Lysophosphatidic acid acyltransferase-β (LPAAT-β) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival Journal Article

  

Authors:	Diefenbach, C. S. M.; Soslow, R. A.; Iasonos, A.; Linkov, I.; Hedvat, C.; Bonham, L.; Singer, J.; Barakat, R. R.; Aghajanian, C.; Dupont, J.
Article Title:	Lysophosphatidic acid acyltransferase-β (LPAAT-β) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival
Abstract:	BACKGROUND. Lysophosphatidic acid acyltransferase-β (LPAAT-β) tumor expression is an emerging prognostic, diagnostic, and therapeutic target in early epithelial ovarian cancer (EOC). The significance of tumor overexpression of LPAAT-β was investigated in a large number of advanced- and early-stage EOC patients. METHODS. LPAAT-β expression was analyzed by immunohistochemistry (IHC) in 158 ovarian tumors, including 68 advanced and 90 low-stage tumors, representing all grades and histologies (including 33 borderline tumors). In advanced-stage patients, tissue from multiple sites was evaluated to assess differential expression of LPAAT-β in local tumor and distant metastases. RESULTS. LPAAT-β was overexpressed in 90 (57%) of all 158 ovarian tumors. Forty-nine (72%) of 68 advanced tumors overexpressed LPAAT-β. LPAAT-β was associated with the presence of carcinoma versus borderline histology (67% vs. 18%, P < .0001), high histologic grade [according to the Silverberg Grading Scheme] (Grade 1, 25%; Grade 2, 21%; and Grade 3, 54%; P < .0001), and with papillary-serous histology. In an analysis of the 125 carcinoma patients, LPAAT-β increased with but was not significantly associated with advanced clinical stage (P = .1431). LPAAT-β expression was associated with shortened progression-free survival (PFS) (5-year PFS, 32% for LPAAT-β-positive vs. 60% for LPAAT-β-negative; P = .0318) and decreased overall survival (OS) (5-year OS, 54% for LPAAT-β-positive vs. 74% for LPAAT-β-negative; P = .0173). CONCLUSIONS. LPAAT-β is highly expressed in advanced ovarian tumors and is associated with aggressive histology and decreased PFS and OS. LPAAT-β is an intriguing prognostic tool for the identification of high-risk EOC and a potential target for directed therapy that warrants further study. © 2006 American Cancer Society.
Keywords:	immunohistochemistry; adolescent; adult; cancer survival; child; human tissue; protein expression; aged; child, preschool; survival analysis; unclassified drug; major clinical study; histopathology; cancer localization; advanced cancer; cancer staging; neoplasm staging; cancer grading; ovarian cancer; ovarian neoplasms; metastasis; ovary cancer; ovary; infant; neoplasm metastasis; acyltransferase; acyltransferases; lysophosphatidic acid acyltransferase-β (lpaat-β); novel target; lysophosphatidic acid acyltransferase beta
Journal Title:	Cancer
Volume:	107
Issue:	7
ISSN:	0008-543X
Publisher:	Wiley Blackwell
Date Published:	2006-10-01
Start Page:	1511
End Page:	1519
Language:	English
DOI:	10.1002/cncr.22184
PUBMED:	16944535
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-33749595083&partnerID=40&md5=58781fad2c6b395643bf83b5283555ce
Notes:	--- - "Cited By (since 1996): 12" - "Export Date: 4 June 2012" - "CODEN: CANCA" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/27197